Bio Plus Statistics
Total Valuation
Bio Plus has a market cap or net worth of KRW 426.14 billion. The enterprise value is 459.04 billion.
Market Cap | 426.14B |
Enterprise Value | 459.04B |
Important Dates
The last earnings date was Wednesday, March 19, 2025.
Earnings Date | Mar 19, 2025 |
Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Bio Plus has 58.14 million shares outstanding. The number of shares has decreased by -3.02% in one year.
Current Share Class | n/a |
Shares Outstanding | 58.14M |
Shares Change (YoY) | -3.02% |
Shares Change (QoQ) | -5.53% |
Owned by Insiders (%) | 33.12% |
Owned by Institutions (%) | 6.43% |
Float | 38.72M |
Valuation Ratios
The trailing PE ratio is 29.68.
PE Ratio | 29.68 |
Forward PE | n/a |
PS Ratio | 6.27 |
PB Ratio | 3.11 |
P/TBV Ratio | 3.39 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.04, with an EV/FCF ratio of -6.70.
EV / Earnings | 32.44 |
EV / Sales | 6.91 |
EV / EBITDA | 17.04 |
EV / EBIT | 19.40 |
EV / FCF | -6.70 |
Financial Position
The company has a current ratio of 0.71, with a Debt / Equity ratio of 0.37.
Current Ratio | 0.71 |
Quick Ratio | 0.57 |
Debt / Equity | 0.37 |
Debt / EBITDA | 2.07 |
Debt / FCF | -0.81 |
Interest Coverage | 89.84 |
Financial Efficiency
Return on equity (ROE) is 12.06% and return on invested capital (ROIC) is 8.32%.
Return on Equity (ROE) | 12.06% |
Return on Assets (ROA) | 6.77% |
Return on Invested Capital (ROIC) | 8.32% |
Return on Capital Employed (ROCE) | 15.11% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.30 |
Inventory Turnover | 2.69 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.17% in the last 52 weeks. The beta is 0.60, so Bio Plus's price volatility has been lower than the market average.
Beta (5Y) | 0.60 |
52-Week Price Change | +5.17% |
50-Day Moving Average | 6,937.00 |
200-Day Moving Average | 6,109.83 |
Relative Strength Index (RSI) | 55.16 |
Average Volume (20 Days) | 934,594 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio Plus had revenue of KRW 66.41 billion and earned 14.15 billion in profits. Earnings per share was 247.00.
Revenue | 66.41B |
Gross Profit | 42.53B |
Operating Income | 23.67B |
Pretax Income | 17.66B |
Net Income | 14.15B |
EBITDA | 26.94B |
EBIT | 23.67B |
Earnings Per Share (EPS) | 247.00 |
Balance Sheet
The company has 41.67 billion in cash and 55.66 billion in debt, giving a net cash position of -13.99 billion or -240.56 per share.
Cash & Cash Equivalents | 41.67B |
Total Debt | 55.66B |
Net Cash | -13.99B |
Net Cash Per Share | -240.56 |
Equity (Book Value) | 152.40B |
Book Value Per Share | 2,355.56 |
Working Capital | -30.85B |
Cash Flow
In the last 12 months, operating cash flow was 26.49 billion and capital expenditures -95.00 billion, giving a free cash flow of -68.51 billion.
Operating Cash Flow | 26.49B |
Capital Expenditures | -95.00B |
Free Cash Flow | -68.51B |
FCF Per Share | -1,178.48 |
Margins
Gross margin is 64.05%, with operating and profit margins of 35.64% and 21.31%.
Gross Margin | 64.05% |
Operating Margin | 35.64% |
Pretax Margin | 26.60% |
Profit Margin | 21.31% |
EBITDA Margin | 40.56% |
EBIT Margin | 35.64% |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.68%.
Dividend Per Share | 50.00 |
Dividend Yield | 0.68% |
Dividend Growth (YoY) | -28.57% |
Years of Dividend Growth | n/a |
Payout Ratio | 29.66% |
Buyback Yield | 3.02% |
Shareholder Yield | 3.70% |
Earnings Yield | 3.32% |
FCF Yield | -16.08% |
Stock Splits
The last stock split was on November 23, 2022. It was a forward split with a ratio of 4.
Last Split Date | Nov 23, 2022 |
Split Type | Forward |
Split Ratio | 4 |
Scores
Bio Plus has an Altman Z-Score of 2.68. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.68 |
Piotroski F-Score | n/a |